betamethasone dipropionate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
prednisone and prednisolone derivatives 353 5593-20-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • betamethasone dipropionate
  • diproderm
  • diprosone
A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)
  • Molecular weight: 504.60
  • Formula: C28H37FO7
  • CLOGP: 3.92
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 1
  • TPSA: 106.97
  • ALOGS: -5.04
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
S (Water solubility) 0.06 mg/mL Bocci G, Oprea TI, Benet LZ

Approvals:

DateAgencyCompanyOrphan
Jan. 29, 1975 FDA SCHERING

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 503.37 16.66 171 8715 24205 63455931
Psoriasis 257.84 16.66 157 8729 86800 63393336
Drug ineffective 128.38 16.66 376 8510 1044389 62435747
Chronic sinusitis 95.41 16.66 43 8843 12800 63467336
Product use in unapproved indication 91.93 16.66 119 8767 178961 63301175
Paraesthesia oral 87.31 16.66 46 8840 19210 63460926
Incorrect route of product administration 82.26 16.66 50 8836 27402 63452734
Procedural pain 79.70 16.66 45 8841 21524 63458612
Steroid withdrawal syndrome 59.06 16.66 14 8872 531 63479605
Dermatitis atopic 49.16 16.66 25 8861 9699 63470437
Vaginal flatulence 48.45 16.66 18 8868 3275 63476861
Erythema 41.52 16.66 82 8804 175669 63304467
Psoriatic arthropathy 41.01 16.66 57 8829 91463 63388673
Proctitis 39.71 16.66 18 8868 5423 63474713
Dyspepsia 39.02 16.66 59 8827 102137 63377999
Female genital tract fistula 36.95 16.66 19 8867 7540 63472596
Therapeutic product effect incomplete 35.31 16.66 63 8823 124993 63355143
Pruritus 33.65 16.66 119 8767 361334 63118802
Radiculopathy 31.89 16.66 18 8868 8593 63471543
Oral candidiasis 31.76 16.66 26 8860 22772 63457364
Vaginal discharge 30.78 16.66 18 8868 9180 63470956
Portal vein cavernous transformation 29.09 16.66 6 8880 118 63480018
Colitis ulcerative 28.72 16.66 26 8860 26065 63454071
Nail psoriasis 28.02 16.66 8 8878 633 63479503
Dry skin 26.33 16.66 36 8850 56851 63423285
Lichenification 25.95 16.66 7 8879 449 63479687
Guttate psoriasis 25.90 16.66 7 8879 452 63479684
Eczema 25.81 16.66 27 8859 32264 63447872
Skin exfoliation 25.81 16.66 31 8855 43071 63437065
Theft 25.40 16.66 5 8881 77 63480059
Rectal haemorrhage 24.17 16.66 32 8854 48998 63431138
Central obesity 22.94 16.66 8 8878 1213 63478923
Skin fissures 22.51 16.66 16 8870 11372 63468764
Bacterial vulvovaginitis 22.10 16.66 7 8879 789 63479347
Toxic neuropathy 21.70 16.66 6 8880 422 63479714
Bacillus infection 21.62 16.66 7 8879 846 63479290
Frequent bowel movements 21.60 16.66 21 8865 23001 63457135
Arthropathy 20.49 16.66 4 8882 234788 63245348
Weight decreased 19.87 16.66 84 8802 276714 63203422
Cellulitis 19.03 16.66 38 8848 81920 63398216
Rheumatoid arthritis 18.90 16.66 6 8880 253813 63226323
Post-traumatic neck syndrome 18.82 16.66 8 8878 2066 63478070
Tachycardia paroxysmal 18.81 16.66 5 8881 303 63479833
Death 18.72 16.66 15 8871 374366 63105770
Lung opacity 18.54 16.66 9 8877 3159 63476977
Libido increased 18.50 16.66 7 8879 1338 63478798
Cutaneous T-cell lymphoma 18.33 16.66 7 8879 1373 63478763
Hepatic function abnormal 17.93 16.66 24 8862 37118 63443018
Skin atrophy 17.48 16.66 10 8876 4896 63475240
Subretinal haematoma 17.39 16.66 3 8883 21 63480115
Weaning failure 17.38 16.66 5 8881 406 63479730
Total bile acids increased 17.21 16.66 4 8882 139 63479997
Skin plaque 17.16 16.66 12 8874 8308 63471828
Soft tissue injury 17.11 16.66 7 8879 1645 63478491
Refractory anaemia with an excess of blasts 16.97 16.66 5 8881 442 63479694
Intraocular haematoma 16.72 16.66 3 8883 27 63480109

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug eruption 319.92 17.66 130 7341 19768 34929692
Hepatic function abnormal 242.15 17.66 138 7333 44225 34905235
Stomatitis 210.05 17.66 124 7347 42390 34907070
Hypersensitivity 182.86 17.66 130 7341 60905 34888555
Urticaria 178.03 17.66 129 7342 62248 34887212
Psoriasis 165.36 17.66 103 7368 38709 34910751
Epistaxis 158.32 17.66 117 7354 58134 34891326
Muscle spasms 146.50 17.66 124 7347 74877 34874583
Pain in extremity 140.29 17.66 153 7318 126360 34823100
Drug ineffective 69.47 17.66 234 7237 456517 34492943
Appendicolith 52.88 17.66 29 7442 8572 34940888
Blood phosphorus increased 50.16 17.66 27 7444 7694 34941766
Pneumonia 44.04 17.66 173 7298 362454 34587006
Appendicitis 42.96 17.66 31 7440 14776 34934684
Myasthenia gravis 38.84 17.66 22 7449 6918 34942542
Blood uric acid increased 37.05 17.66 24 7447 9600 34939860
Pulmonary vasculitis 33.72 17.66 10 7461 589 34948871
Pruritus 32.07 17.66 84 7387 141897 34807563
Polydipsia 32.07 17.66 16 7455 3899 34945561
Toxicity to various agents 31.95 17.66 3 7468 200359 34749101
Cardiogenic shock 30.75 17.66 33 7438 26585 34922875
Incorrect route of product administration 29.81 17.66 25 7446 14820 34934640
Erythrodermic psoriasis 29.63 17.66 10 7461 897 34948563
Neuritis 29.35 17.66 10 7461 924 34948536
Psoriatic arthropathy 29.18 17.66 28 7443 19770 34929690
Blood cholesterol increased 26.47 17.66 27 7444 20516 34928944
Respiratory symptom 26.30 17.66 11 7460 1786 34947674
Ventricular fibrillation 25.71 17.66 28 7443 22926 34926534
Stress 25.61 17.66 32 7439 30315 34919145
Therapeutic product effect incomplete 21.93 17.66 39 7432 50502 34898958
Skin exfoliation 21.68 17.66 28 7443 27404 34922056
Adrenal insufficiency 19.08 17.66 19 7452 14028 34935432
Drug interaction 18.31 17.66 13 7458 225933 34723527
African trypanosomiasis 18.20 17.66 3 7468 9 34949451
Dry mouth 18.15 17.66 27 7444 30138 34919322
Ascites 17.76 17.66 34 7437 46537 34902923

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Psoriasis 349.66 14.11 213 14474 89374 79640327
Drug eruption 270.66 14.11 141 14546 43794 79685907
Hepatic function abnormal 240.33 14.11 156 14531 72951 79656750
Urticaria 117.31 14.11 157 14530 185044 79544657
Stomatitis 116.08 14.11 139 14548 146618 79583083
Epistaxis 110.93 14.11 119 14568 111396 79618305
Incorrect route of product administration 103.66 14.11 70 14617 34859 79694842
Pain in extremity 95.02 14.11 208 14479 364330 79365371
Muscle spasms 89.68 14.11 134 14553 174596 79555105
Macular degeneration 83.35 14.11 41 14646 11255 79718446
Chronic sinusitis 80.68 14.11 42 14645 12984 79716717
Product use in unapproved indication 73.42 14.11 150 14537 250209 79479492
Paraesthesia oral 72.90 14.11 46 14641 20425 79709276
Drug ineffective 70.55 14.11 387 14300 1080526 78649175
Procedural pain 63.13 14.11 44 14643 23040 79706661
Appendicolith 57.08 14.11 29 14658 8522 79721179
Hypersensitivity 51.29 14.11 134 14553 262105 79467596
Vaginal flatulence 47.94 14.11 18 14669 2557 79727144
Psoriatic arthropathy 47.57 14.11 65 14622 77934 79651767
Blood phosphorus increased 46.50 14.11 27 14660 10320 79719381
Therapeutic product effect incomplete 44.00 14.11 87 14600 141558 79588143
Toxicity to various agents 43.38 14.11 12 14675 421528 79308173
Appendicitis 41.93 14.11 33 14654 20761 79708940
Pruritus 39.99 14.11 161 14526 394487 79335214
Erythrodermic psoriasis 39.07 14.11 14 14673 1744 79727957
Erythema 37.55 14.11 108 14579 223182 79506519
Female genital tract fistula 36.24 14.11 19 14668 5956 79723745
Myasthenia gravis 36.10 14.11 23 14664 10376 79719325
Drug interaction 34.03 14.11 17 14670 415166 79314535
Blood uric acid increased 33.14 14.11 24 14663 13336 79716365
Pulmonary vasculitis 32.82 14.11 10 14677 751 79728950
Proctitis 32.17 14.11 18 14669 6414 79723287
Dermatitis atopic 31.86 14.11 21 14666 10035 79719666
Vaginal discharge 29.69 14.11 18 14669 7445 79722256
Skin fissures 29.09 14.11 22 14665 13051 79716650
Steroid withdrawal syndrome 29.08 14.11 9 14678 712 79728989
Neuritis 28.11 14.11 11 14676 1747 79727954
Portal vein cavernous transformation 27.17 14.11 6 14681 124 79729577
Radiculopathy 26.92 14.11 18 14669 8806 79720895
Oral candidiasis 26.61 14.11 30 14657 29598 79700103
Polydipsia 26.45 14.11 16 14671 6589 79723112
Skin exfoliation 26.43 14.11 41 14646 55059 79674642
Eczema 26.38 14.11 35 14652 40783 79688918
Dyspepsia 25.94 14.11 60 14627 108627 79621074
Cellulitis 25.80 14.11 60 14627 109000 79620701
Pneumonia 24.97 14.11 207 14480 660039 79069662
Guttate psoriasis 23.88 14.11 7 14680 460 79729241
Dry skin 23.85 14.11 44 14643 67951 79661750
Rheumatoid arthritis 23.24 14.11 5 14682 208465 79521236
Cardiogenic shock 22.68 14.11 33 14654 41881 79687820
Adrenal insufficiency 22.50 14.11 27 14660 28460 79701241
Arthropathy 22.49 14.11 3 14684 177108 79552593
Hypotension 22.37 14.11 29 14658 440288 79289413
Bacterial vulvovaginitis 22.10 14.11 7 14680 598 79729103
Pemphigoid 22.01 14.11 20 14667 15295 79714406
Nail psoriasis 21.65 14.11 7 14680 638 79729063
Ventricular fibrillation 21.60 14.11 28 14659 31898 79697803
Skin lesion 21.28 14.11 32 14655 41812 79687889
Central obesity 21.24 14.11 9 14678 1752 79727949
Skin atrophy 20.73 14.11 13 14674 5705 79723996
Male genital atrophy 20.72 14.11 3 14684 3 79729698
Colitis ulcerative 19.75 14.11 28 14659 34714 79694987
Skin plaque 19.43 14.11 16 14671 10729 79718972
Stress 19.04 14.11 44 14643 79568 79650133
African trypanosomiasis 18.40 14.11 3 14684 10 79729691
Seizure 18.26 14.11 6 14681 188828 79540873
Bacillus infection 17.67 14.11 7 14680 1148 79728553
Respiratory symptom 17.64 14.11 11 14676 4780 79724921
Cell marker increased 17.60 14.11 6 14681 645 79729056
Spontaneous ejaculation 17.60 14.11 3 14684 14 79729687
Iron deficiency 17.48 14.11 15 14672 10639 79719062
Toxic skin eruption 17.39 14.11 21 14666 22272 79707429
Inappropriate schedule of product administration 17.24 14.11 59 14628 133569 79596132
Contraindicated product administered 17.11 14.11 4 14683 157534 79572167
Frequent bowel movements 17.07 14.11 24 14663 29515 79700186
Hypothalamic pituitary adrenal axis suppression 17.04 14.11 5 14682 330 79729371
Post-traumatic neck syndrome 16.65 14.11 8 14679 2086 79727615
Tachycardia paroxysmal 16.15 14.11 5 14682 396 79729305
Asthenia 16.06 14.11 45 14642 511644 79218057
Splenic granuloma 15.35 14.11 3 14684 33 79729668
Erysipelas 15.26 14.11 14 14673 10836 79718865
Toxic neuropathy 15.21 14.11 6 14681 974 79728727
Cushing's syndrome 15.12 14.11 6 14681 989 79728712
Skin irritation 14.84 14.11 14 14673 11226 79718475
Soft tissue injury 14.75 14.11 7 14680 1774 79727927
Cutaneous T-cell lymphoma 14.72 14.11 8 14679 2695 79727006
Malaise 14.60 14.11 146 14541 489723 79239978
Shared psychotic disorder 14.55 14.11 3 14684 44 79729657
Lung opacity 14.46 14.11 10 14677 5164 79724537
Erythema multiforme 14.38 14.11 17 14670 17634 79712067
Synovitis 14.21 14.11 5 14682 150729 79578972
Death 14.21 14.11 55 14632 566459 79163242

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000175450 Corticosteroid Hormone Receptor Agonists
FDA EPC N0000175576 Corticosteroid
MeSH PA D000893 Anti-Inflammatory Agents
CHEBI has role CHEBI:35472 anti-inflammatory drugs
CHEBI has role CHEBI:35705 immunosuppressive agents
CHEBI has role CHEBI:65023 anti-asthmatic agents
MeSH PA D018927 Anti-Asthmatic Agents
MeSH PA D005938 Glucocorticoids
MeSH PA D006728 Hormones
MeSH PA D019141 Respiratory System Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Tinea pedis indication 6020002 DOID:12403
Atopic dermatitis indication 24079001 DOID:3310
Contact dermatitis indication 40275004 DOID:2773
Seborrheic dermatitis indication 50563003 DOID:8741
Lichen simplex chronicus indication 53891004
Granuloma annulare indication 65508009 DOID:3777
Tinea corporis indication 84849002
Pruritus ani indication 90446007
Discoid lupus erythematosus indication 200938002
Plaque psoriasis indication 200965009
Scalp psoriasis indication 238608008
Pruritus of genital organs indication 267802000
Eruption of skin indication 271807003 DOID:0050486
Tinea cruris indication 399029005
Primary cutaneous T-cell lymphoma indication 400122007
Psoriasis off-label use 9014002 DOID:8893
Congenital ichthyosis of skin contraindication 13059002
Hypervitaminosis D contraindication 27712000 DOID:9971
Guttate psoriasis contraindication 37042000
Hypercalcemia contraindication 66931009 DOID:12678
Disorder of calcium metabolism contraindication 71638002 DOID:10575
Hypercalciuria contraindication 71938000
Pustular psoriasis contraindication 200973000
Telangiectasia disorder contraindication 247479008
Adrenal cortical hypofunction contraindication 386584007 DOID:10493
Atrophoderma contraindication 399979006
Peripheral vascular disease contraindication 400047006




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Pruritus associated with dermatoses Indication
Dogs Pruritus associated with dermatoses Indication
Horses Inflammatory joint conditions Indication

🐶 Veterinary products

ProductApplicantIngredients
Betasone Aqueous Suspension Intervet Inc. 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.48 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 10179137 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9364485 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9433630 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9439911 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9655907 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9775851 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
EQ 0.05% BASE/SPRAY SERNIVO PRIMUS PHARMS N208079 Feb. 5, 2016 RX SPRAY TOPICAL 9877974 Aug. 31, 2030 TREATMENT OF PLAQUE PSORIASIS
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 10660908 June 10, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 10688108 June 10, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 9119781 June 10, 2031 PLAQUE PSORIASIS
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL 9119781 June 10, 2031 TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
0.064%;0.005% TACLONEX LEO PHARMA AS N022185 May 9, 2008 RX SUSPENSION TOPICAL Jan. 25, 2023 PEDIATRIC EXCLUSIVITY
0.064%;0.005% ENSTILAR LEO PHARMA AS N207589 Oct. 16, 2015 RX AEROSOL, FOAM TOPICAL Jan. 30, 2023 PEDIATRIC EXCLUSIVITY
0.064%;0.005% WYNZORA MC2 N213422 July 20, 2020 RX CREAM TOPICAL July 20, 2023 NEW DOSAGE FORM

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Glucocorticoid receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL
Glucocorticoid receptor Transcription factor IC50 8.28 CHEMBL

External reference:

IDSource
4018642 VUID
N0000179052 NUI
D01637 KEGG_DRUG
1514 RXNORM
C0053523 UMLSCUI
CHEBI:3077 CHEBI
CHEMBL1200384 ChEMBL_ID
C011175 MESH_SUPPLEMENTAL_RECORD_UI
826Y60901U UNII
21800 PUBCHEM_CID
DB00443 DRUGBANK_ID
10006 MMSL
129 MMSL
31630 MMSL
3190 MMSL
4270 MMSL
4273 MMSL
d00628 MMSL
116571008 SNOMEDCT_US
29896003 SNOMEDCT_US
88736007 SNOMEDCT_US
C0005308 UMLSCUI
4018642 VANDF
4018644 VANDF
1045 INN_ID
9782 PUBCHEM_CID
D001623 MESH_DESCRIPTOR_UI
002168 NDDF
002171 NDDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lotrisone HUMAN PRESCRIPTION DRUG LABEL 2 0085-0924 CREAM 0.50 mg TOPICAL NDA 26 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0055 CREAM 0.50 mg TOPICAL NDA 18 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0056 OINTMENT 0.50 mg TOPICAL NDA 18 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0057 LOTION 0.50 mg TOPICAL ANDA 18 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0168-0258 CREAM 0.50 mg TOPICAL ANDA 27 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0265 CREAM, AUGMENTED 0.50 mg TOPICAL ANDA 27 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0267 LOTION, AUGMENTED 0.50 mg TOPICAL ANDA 27 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0267 LOTION, AUGMENTED 0.50 mg TOPICAL ANDA 27 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0168-0268 OINTMENT, AUGMENTED 0.50 mg TOPICAL ANDA 27 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0168-0370 LOTION 0.50 mg TOPICAL ANDA 20 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0472-0379 CREAM 0.50 mg TOPICAL ANDA 24 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 0472-0379 CREAM 0.50 mg TOPICAL ANDA 24 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0380 CREAM 0.50 mg TOPICAL ANDA 10 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0381 OINTMENT 0.50 mg TOPICAL ANDA 10 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0381 OINTMENT 0.50 mg TOPICAL ANDA 10 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0382 OINTMENT, AUGMENTED 0.50 mg TOPICAL ANDA 26 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0472-0382 OINTMENT, AUGMENTED 0.50 mg TOPICAL ANDA 26 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0659 CREAM 0.50 mg TOPICAL ANDA 10 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0659 CREAM 0.50 mg TOPICAL ANDA 10 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0728 LOTION 0.50 mg TOPICAL ANDA 11 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0728 LOTION 0.50 mg TOPICAL ANDA 11 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0759 CREAM 0.50 mg TOPICAL ANDA 11 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0759 CREAM 0.50 mg TOPICAL ANDA 11 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0807 LOTION 0.50 mg TOPICAL ANDA 11 sections
Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0807 LOTION 0.50 mg TOPICAL ANDA 11 sections
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE HUMAN PRESCRIPTION DRUG LABEL 2 0781-7165 OINTMENT 0.50 mg TOPICAL ANDA 22 sections
BETAMETHASONE DIPROPIONATE HUMAN PRESCRIPTION DRUG LABEL 1 16590-032 CREAM 0.64 mg TOPICAL ANDA 18 sections
BETAMETHASONE CLOTRIMAZOLE HUMAN PRESCRIPTION DRUG LABEL 2 16590-033 CREAM 0.64 mg TOPICAL ANDA 12 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 16714-496 CREAM 0.64 mg TOPICAL ANDA 28 sections
Clotrimazole and Betamethasone Dipropionate HUMAN PRESCRIPTION DRUG LABEL 2 16714-496 CREAM 0.64 mg TOPICAL ANDA 28 sections